Taisho Pharmaceutical Co., Ltd.

Yuki Iwata

Hiroyuki Kakinuma

Takahiro Oi

Yohei Kobashi

Fumiyasu Shiozawa

Tomomichi Chonan

Kenichi Kawabe

Hitomi Takahashi

Hideaki Amada

Yuko Hashimoto

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided: 

4-isopropyl-6-methoxyphenyl glucitol compound

The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein Rrepresents a hydrogen atom, etc., Rrepresents a methyl group, etc., Rrepresents a Calkyl group substituted with an amino group(s), etc., and Rrepresents a hydrogen atom, etc.

4-isopropylphenyl glucitol compounds as SGLT1 inhibitors

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof  

C-phenyl glycitol compound

Growing community of inventors

Toshima-ku, Japan

Yuki Iwata